Research progress in immunotherapy of thymic epithelial tumors
10.3969/j.issn.1671-8348.2025.04.033
- VernacularTitle:胸腺上皮肿瘤免疫治疗的研究进展
- Author:
Xuanlu HE
1
;
Qi ZHANG
;
Yiyun SU
;
Yu ZHANG
Author Information
1. 遵义医科大学第一临床学院,贵州遵义 563000;贵州省人民医院肿瘤科,贵阳 550000
- Keywords:
thymic epithelial tumors;
immune check-point inhibitors;
immune-related adverse events;
thymus;
immunotherapy
- From:
Chongqing Medicine
2025;54(4):977-982,988
- CountryChina
- Language:Chinese
-
Abstract:
A rising frequency of thymic epithelial tumors has been noted recent years,however limited drugs can be chosen for recurrent and metastatic thymic epithelial tumors patients.Treatment patterns in mul-tiple tumors have been rapidly developing in parallel with the growing use of immune checkpoint inhibitors(ICIs).Although ICIs have showed certain efficacy in thymic epithelial tumors patients,the relatively high in-cidence of immune-related adverse events(irAEs)limited its application.This review aims to summary the ef-ficacy,side effects and related mechanisms of ICIs for treating thymic epithelial tumors patient,which may shed light on the predicament of immunotherapy for thymic epithelial tumors patients.
